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Abstract 
Case report on a case of t(1;3)(p36;p21) and other 
aberrations in a case of AML secondary to MDS. 
Clinics 
Age and sex 
45 years old male patient. 
Previous history 
Preleukemia MDS-RAEB1 (6,6% blasts BM, 
normal karyotype) (03/2008), no previous 
malignancy, no inborn condition of note.  
Organomegaly 
No hepatomegaly, no splenomegaly, no enlarged 
lymph nodes, no central nervous system 
involvement.  
Blood 
WBC: 101 X 109/l 
HB: 9,3g/dl 
Platelets: 18 X 109/l 
Blasts: 92% (PB) 
Bone marrow: blasts: 87%, red cells: 1% and 
lymphocytes: 12% 
Cyto-Pathology 
Classification 
Immunophenotype 
CD15-/+ (35%),CD33-/+ (17%), CD34-/+ (64%), 
CD45+/++, CD64-/+ weak, CD117+/++, CD123+, 
HLA-DR+/+++ heterogeneous. Negativity: CD3, 
CD4,CD8, CD36. 
Pathology 
Acute Myeloid Leukemia, M2 
Survival 
Date of diagnosis: 03-2008 
Treatment 
Allogenic Bone Marrow Transplantation: 1st 04-
2008 and 2nd 08-2009. The patient was treated with 
alkylating agents (cyclophosphamide and Busulfan) 
during conditioning regimen for the first bone 
marrow transplantation. For the second one, it was 
used cyclophosphamide and TBI (total body 
irradiation). 
Complete remission: complete remission was 
obtained 
Treatment related death: no  
Relapse: + 
Status: Dead 
Last follow up: 04-2013 
Survival: 49 months 
Karyotype 
Sample: Bone marrow 
Culture time: 24h 
Banding: GTG 
Results 
46,XY,t(1;3)(p36.2;p21),t(4;5)(q31;q35),t(5;16)(q1
3;p13.3),del(7)(p15),t(13;22)(q13;q13)[20] 
Translocation t(1;3)(p36;p21) and other aberrations in a case of AML secondary to MDS  Schmid Braz AT et al 
 
 
 
 
 
Atlas Genet Cytogenet Oncol Haematol. 2014; 18(3) 223 
 
Partial karyotypes with G-banding showing the t(1;3)(p36.2;p21) 
 
Comments 
The patient was diagnosed as MDS-RAEB1 in 
2008. In the same year he underwent a bone 
marrow transplantation. One year after (2009) he 
relapsed as sAML. He was submitted to a second 
HSCT. He was in remission until 2011, when the 
disease relapsed as AML. In 2012 a third remission 
was achieved.  
In 2013 he relapsed as AML M2 after the last 
therapy. At this point he presented this complex 
karyotype: 
46,XY,t(1;3)(p36.2;p21),t(4;5)(q31;q35),t(5;16)(q1
3;p13.3),del(7)(p15),t(13;22)(q13;q13). Data 
reported in literature suggest that 3p21 is a 
recurrent treatment-related breakpoint in MDS and 
AML (Shi et al., 1996). The t(1;3)(p36;p21) is a 
recurring chromosomal translocation and it was 
described after treatment with alkylating agent in 
several cases (Sato et al., 2002). Our patient was 
also treated with alkylating agents 
(cyclophosphamide and Busulfan) during 
conditioning regimen for the first bone marrow 
transplantation. For the second one, it was used 
cyclophosphamide and TBI (total body irradiation). 
Sato et al., 2002 and other reports have described a 
high frequency of abnormalities of chromosomes 5 
and 7 (Smith et al., 2003) as part of a complex 
karyotype in patients with t(1;3). In our report, we 
could observe both chromosome 5 involved in 
different aberrations. It was not possible to prove 
all the aberrations with FISH (not available in our 
service) and also we couldn't find t(13;22) in other 
reports. 
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